Medical Devices

The PD-L1 biomarker testing market is set to double by 2036, fueling a revolution in cancer care. But as innovation races ahead, who gets left behind?

A pilot study shows light therapy improving memory in MCI patients, fueling the at-home neurotech boom. But can Vielight turn scientific promise into market reality?

With the acquisition of an FDA-cleared app, UpRight Science is turning smartphones into medical devices to predict and prevent falls in older adults.

A major survey names Bonafide Health's products #1 in their class. We explore the strategy behind the headlines and what it signals for women's health.

A record $1.15M campaign for blood cancer reveals a new playbook where executive influence, not just corporate checks, drives profound social impact.

A look at how a Massachusetts ABA provider turns clinical assessments into a viable business blueprint, using expert insights and innovative media to scale trust.

In a strategic pivot, GeneDx brings in former Quest and Thermo Fisher exec Mark Gardner to translate its genomic leadership into commercial dominance.

A small med-tech firm is betting its future on fingerprint sweat. Can its novel drug test pass the FDA's rigorous trials and disrupt a billion-dollar market?

Quoin Pharma's new data for a rare skin disease shows life-changing results in children, offering hope for families. What do the numbers really mean?

With patient dosing underway for its fibroblast-based DFU therapy, FibroBiologics is testing a new paradigm: healing chronic wounds from within.

Millions of adults are straightening their teeth, but not with braces. We examine the tech, economics, and human behavior driving the clear aligner boom.

A new corporate alliance is targeting veteran lung disease. It’s more than a webinar; it’s a strategic response to the PACT Act’s seismic shift.

Carta Healthcare’s expansion highlights a critical trend: AI’s real value in medicine isn’t automation, but augmenting expert clinicians. We analyze the impact.

Adial Pharmaceuticals pivots from addiction to inflammation, securing $32M and poaching Azora's leadership to drive its new ulcerative colitis drug, AT177.

A guidance cut at Sanuwave reveals a deeper crisis in wound care, driven by CMS policy shifts that are fueling a disruptive secondary equipment market.

BioAge Labs starts a Phase 2 trial for BGE-102, an oral drug targeting inflammation to reduce heart risk, a strategy that could redefine cardiovascular care.

The at-home beauty tech giant is betting on immersive, influencer-led wellness events to conquer the US market. Is this the future of brand building?

Baptist Health's re-accreditation in the Cayman Islands is more than a quality seal. It’s a blueprint for a new economic and healthcare model in the Caribbean.

Eli Lilly's Zepbound secures a landmark approval for sleep apnea, moving beyond weight loss to redefine chronic disease management and challenge competitors.

Arima Genomics' award-winning Aventa test is revolutionizing lymphoma diagnostics by seeing cancer in 3D, moving beyond 2D methods to find what others miss.